Research ArticleArticle
Open Access
Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort
Murray B. Urowitz, Dafna D. Gladman, Dominique Ibañez, Jiandong Su, Sara Mursleen, Amyn Sayani, Jorge Alfonso Ross Terres and Sandra Iczkovitz
The Journal of Rheumatology April 2020, jrheum.190259; DOI: https://doi.org/10.3899/jrheum.190259
Murray B. Urowitz
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Dafna D. Gladman
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Dominique Ibañez
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Jiandong Su
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Sara Mursleen
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Amyn Sayani
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Jorge Alfonso Ross Terres
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
Sandra Iczkovitz
This study was funded by GlaxoSmithKline Inc. (GSK; study number 201390). M.B. Urowitz, MD, D.D. Gladman, MD, D. Ibañez, MSc, J. Su, MSc, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; 2S. Mursleen, MSc, A. Sayani, PhD, S. Iczkovitz, MSc, GlaxoSmithKline Inc., Toronto, Ontario, Canada; 3J.A.R. Terres, MD, GlaxoSmithKline Inc., Toronto, Ontario, Canada, and GlaxoSmithKline Inc., Philadelphia, Pennsylvania, USA. JART and SM are employees of GSK. AS was an employee of GSK at the time of the study. AS and JART hold stocks in GSK. SI was an employee of GSK during the development of the manuscript. MBU has received consulting fees and research grants from GSK, UCB, and Eli Lilly. DDG reports consulting for GSK, BMS, Janssen, UCB, and Eli Lilly. Address correspondence to Prof. M.B. Urowitz, Toronto Western Hospital, 399 Bathurst Street, 1E409, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication March 18, 2020.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort
Murray B. Urowitz, Dafna D. Gladman, Dominique Ibañez, Jiandong Su, Sara Mursleen, Amyn Sayani, Jorge Alfonso Ross Terres, Sandra Iczkovitz
The Journal of Rheumatology Apr 2020, jrheum.190259; DOI: 10.3899/jrheum.190259
Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort
Murray B. Urowitz, Dafna D. Gladman, Dominique Ibañez, Jiandong Su, Sara Mursleen, Amyn Sayani, Jorge Alfonso Ross Terres, Sandra Iczkovitz
The Journal of Rheumatology Apr 2020, jrheum.190259; DOI: 10.3899/jrheum.190259